[Advances in the treatment of aplastic anemia].
The purpose of this paper is to describe the current advances in the pathogenesis, classification and treatment of acquired aplastic anemia (AA). The therapeutical experience obtained at the Servicio de Hematología, Centro Medico Nacional, Siglo XXI is described. Bone marrow transplantation is the first choice therapy for severe AA. This procedure succeeds in obtaining complete remission in nearly 80% of the cases. Nevertheless, few patients are eligible for such therapy, consequently other treatments should be considered. In this context some immunosuppressive therapies such as antilymphocyte globulin had shown to produce favorable responses in 60% of the patients. In addition, androgens and immunosuppressive drugs like methylprednisolone bolus and cyclosporin A do not have a definitive place in severe AA. Finally, it is important to describe the experience with lymphocytapheresis, a new procedure, that decreases the immunological response against the normal hematopoiesis by removing the population of T-lymphocytes inducing complete remission in a few patients.
Morales Polanco
M R
MR
Servicio de Hematología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS.
Sánchez Valle
E
E
Chávez Sánchez
G
G
Guillén Mariscal
C
C
Gómez Morales
E
E
Pizzuto Chávez
J
J
D000741:Anemia, Aplastic / Q000503:physiopathology / Q000628:therapy*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007937:Leukapheresis; D013601:T-Lymphocytes / Q000276:immunology; D045165:Testosterone Congeners / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D005938:Glucocorticoids; D045165:Testosterone Congeners; D016572:Cyclosporine
Avances en el tratamiento de la anemia aplástica.